These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 22595047)

  • 1. Sipuleucel-T for the treatment of advanced prostate cancer.
    Frohlich MW
    Semin Oncol; 2012 Jun; 39(3):245-52. PubMed ID: 22595047
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of sipuleucel-T: autologous cellular immunotherapy for the treatment of metastatic castrate resistant prostate cancer.
    Sims RB
    Vaccine; 2012 Jun; 30(29):4394-7. PubMed ID: 22122856
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sipuleucel-T: APC 8015, APC-8015, prostate cancer vaccine--Dendreon.
    Drugs R D; 2006; 7(3):197-201. PubMed ID: 16752945
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sipuleucel-T (Provenge): active cellular immunotherapy for advanced prostate cancer.
    McKarney I
    Issues Emerg Health Technol; 2007 Sep; (101):1-4. PubMed ID: 17763575
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotherapy in castration-resistant prostate cancer: integrating sipuleucel-T into our current treatment paradigm.
    Garcia JA; Dreicer R
    Oncology (Williston Park); 2011 Mar; 25(3):242-9. PubMed ID: 21548467
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sipuleucel-T (Provenge®) for castration-resistant prostate cancer.
    Di Lorenzo G; Ferro M; Buonerba C
    BJU Int; 2012 Jul; 110(2 Pt 2):E99-104. PubMed ID: 22177289
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Building on sipuleucel-T for immunologic treatment of castration-resistant prostate cancer.
    Shore ND; Mantz CA; Dosoretz DE; Fernandez E; Myslicki FA; McCoy C; Finkelstein SE; Fishman MN
    Cancer Control; 2013 Jan; 20(1):7-16. PubMed ID: 23302902
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostate Cancer Immunotherapy with Sipuleucel-T: Current Standards and Future Directions.
    Wei XX; Fong L; Small EJ
    Expert Rev Vaccines; 2015; 14(12):1529-41. PubMed ID: 26488270
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sipuleucel-T for the treatment of prostate cancer: novel insights and future directions.
    Handy CE; Antonarakis ES
    Future Oncol; 2018 Apr; 14(10):907-917. PubMed ID: 29260582
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sipuleucel-T: Prototype for development of anti-tumor vaccines.
    Carballido E; Fishman M
    Curr Oncol Rep; 2011 Apr; 13(2):112-9. PubMed ID: 21243538
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sipuleucel-T (APC8015) for prostate cancer.
    So-Rosillo R; Small EJ
    Expert Rev Anticancer Ther; 2006 Sep; 6(9):1163-7. PubMed ID: 17020451
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Beyond sipuleucel-T: immune approaches to treating prostate cancer.
    Cheng ML; Fong L
    Curr Treat Options Oncol; 2014 Mar; 15(1):115-26. PubMed ID: 24402184
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New treatment options for castration-resistant prostate cancer.
    Simondsen K; Kolesar J
    Am J Health Syst Pharm; 2013 May; 70(10):856-65. PubMed ID: 23640346
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sipuleucel-T for prostate cancer: the immunotherapy era has commenced.
    Buonerba C; Ferro M; Di Lorenzo G
    Expert Rev Anticancer Ther; 2011 Jan; 11(1):25-8. PubMed ID: 21166508
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunotherapy for metastatic prostate cancer: where are we at with sipuleucel-T?
    Lü C; Williams AK; Chalasani V; Martínez CH; Chin J
    Expert Opin Biol Ther; 2011 Jan; 11(1):99-108. PubMed ID: 21080858
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotherapy for advanced prostate cancer: a novel treatment option to improve survival.
    Peskin SR
    Manag Care; 2011 Sep; 20(9 Suppl 5):3-4, 6-11. PubMed ID: 22046617
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine.
    Cheever MA; Higano CS
    Clin Cancer Res; 2011 Jun; 17(11):3520-6. PubMed ID: 21471425
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Survival Outcomes of Sipuleucel-T Phase III Studies: Impact of Control-Arm Cross-Over to Salvage Immunotherapy.
    George DJ; Nabhan C; DeVries T; Whitmore JB; Gomella LG
    Cancer Immunol Res; 2015 Sep; 3(9):1063-9. PubMed ID: 25943532
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sipuleucel-T (Provenge) autologous vaccine approved for treatment of men with asymptomatic or minimally symptomatic castrate-resistant metastatic prostate cancer.
    Gardner TA; Elzey BD; Hahn NM
    Hum Vaccin Immunother; 2012 Apr; 8(4):534-9. PubMed ID: 22832254
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer.
    Higano CS; Schellhammer PF; Small EJ; Burch PA; Nemunaitis J; Yuh L; Provost N; Frohlich MW
    Cancer; 2009 Aug; 115(16):3670-9. PubMed ID: 19536890
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.